Skip to content
10-Q

Quarterly Report

Asterias Biotherapeutics, Inc.

0001140361-17-042874

← back to feed
Filed
Nov 14, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q3 2017 · Sep 30, 2017 $8.62M
Cash And Equivalents Q3 2017 · Dec 31, 2016 $19.8M
Cash And Equivalents Q3 2017 · Sep 30, 2016 $17.93M
Cash And Equivalents Q3 2017 · Dec 31, 2015 $11.18M
Stockholders Equity Q3 2017 · Sep 30, 2017 $31.73M
Stockholders Equity Q3 2017 · Dec 31, 2016 $42.03M
Current Liabilities Q3 2017 · Sep 30, 2017 $2.38M
Current Liabilities Q3 2017 · Dec 31, 2016 $6.05M
Total Liabilities Q3 2017 · Sep 30, 2017 $11.59M
Total Liabilities Q3 2017 · Dec 31, 2016 $18.98M
Current Assets Q3 2017 · Sep 30, 2017 $21.93M
Current Assets Q3 2017 · Dec 31, 2016 $36.99M
Total Assets Q3 2017 · Sep 30, 2017 $43.32M
Total Assets Q3 2017 · Dec 31, 2016 $61.01M
Capex Q3 2017 · Sep 30, 2016 $643K
Operating Cash Flow Q3 2017 · Sep 30, 2016 −$15.08M
Sga Expense Q3 2017 · Sep 30, 2016 $4.21M
Sga Expense Q3 2017 · Sep 30, 2016 $13.08M
Rd Expense Q3 2017 · Sep 30, 2016 $5.23M
Rd Expense Q3 2017 · Sep 30, 2016 $17.59M
Net Income Q3 2017 · Sep 30, 2016 −$10.65M
Net Income Q3 2017 · Sep 30, 2016 −$26.14M
Operating Income Q3 2017 · Sep 30, 2016 −$7.43M
Operating Income Q3 2017 · Sep 30, 2016 −$25.59M
Gross Profit Q3 2017 · Sep 30, 2016 $2.02M
Gross Profit Q3 2017 · Sep 30, 2016 $5.08M
Cost Of Revenue Q3 2017 · Sep 30, 2016 $59K
Cost Of Revenue Q3 2017 · Sep 30, 2016 $118K